Clinical trials: CMV
Precancerous/Nonmalignant Condition
Cytomegalovirus Vaccine in Healthy Participants
RATIONALE: Vaccines may help the body build an effective immune response against cytomegalovirus. PURPOSE: This randomized phase I trial is studying the side effects and best dose of cytomegalovirus vaccine in healthy…
- Trial name
- NCT00712634
- Testing
- CMVpp65-A*0201 peptide vaccine
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Pregnant Women Undergoing TOP, TOP - Failed Attempted Termination of Pregnancy
Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Randomized Against Valaciclovir - CYMEVALIII STEP1
In the model of the perfused cotyledon, Letermovir crosses the placenta to reach appropriate fetal concentration. The cotyledon model can only be performed in the third trimester placenta.
- Trial name
- CYMEVAL3-STEP1 (NCT04732260)
- Testing
- Letermovir
- Where
- France
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Congenital Cytomegalovirus Infection, Cytomegalovirus Infection Reactivation
A Cohort Study of Congenital Cytomegalovirus Infection Among Pregnant Women and Their Newborns in China
The purpose of this study is to assess the risk of congenital cytomegalovirus (cCMV) infection in newborns born to seropositive women.
- Trial name
- NCT02645396
- Where
- 2 sites in China
- Volunteers
- 8,855 people, healthy volunteers welcome
- Sponsor
- Jun Zhang
CMV
Effect of Atorvastatin on Subclinical Atherosclerosis
Statin administration is supposed to reduce subclinical atherosclerosis by decreasing LDL cholesterol levels, possibly via lipid-independent anti-inflammatory effect.
- Trial name
- NCT04101136
- Where
- Indonesia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Dr Cipto Mangunkusumo General Hospital
Acute Bacterial Infections, Acute Viral Infections
300 Antibody Diagnostic Test Kit
For the development of a Point of Care IVD test kit for acute phase disease detection against a variety of bacterial and viral infections.
- Trial name
- Antibody 300 (NCT01646411)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- The Plasma Source
CMV
Detection of Cytomegalovirus Virus in Neonates
To evaluate the illumigene CMV assay, using the illumipro-10 with neonates (up to 21 days of age) saliva swabs
- Trial name
- CMV (NCT03251261)
- Testing
- illumigene CMV assay, illumipro-10
- Where
- 5 sites in United States, Australia and 2 more
- Volunteers
- 1,615 people, healthy volunteers welcome
- Sponsor
- Meridian Bioscience, Inc.
Neoplasms
Impaired Immunity in Patients With Cancer: Influence of Cancer Stage, Chemotherapy, and Cytomegalovirus Infection
According to a survey from Department of Health in 2004, cancer has been the leading cause of death in the Taiwan area. In 2004, people died of cancer, accounting for 27.2 percent of all deaths.
- Trial name
- NCT00521287
- Testing
- Immune profiling and DC vaccine
- Where
- Taiwan
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Mackay Memorial Hospital
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV)…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Trial name
- NCT06059391
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Granulocyte Colony-Stimulating Factor
- Where
- 3 sites in United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Cytomegalovirus Infection
Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults
This clinical study will assess the safety and immunogenicity of 3 dose levels of mRNA-1647 cytomegalovirus vaccine in CMV-seronegative and CMV-seropositive healthy adults 18-40 years of age.
- Trial name
- NCT04232280
- Testing
- mRNA-1647
- Where
- 9 sites in United States
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Congenital Cytomegalovirus, Cytomegalovirus Infections
Protein Biomarkers and Host RNA Expression Profiles in Congenital Cytomegalovirus Infection
This study seeks to identify and test host protein biomarkers and RNA expression profiles in dried blood spot samples as novel diagnostic markers of congenital cytomegalovirus sequelae and to improve the understanding of the…
- Conditions
- Congenital Cytomegalovirus, Cytomegalovirus Infections, Neonatal Infection, Sensorineural Hearing Loss
- Trial name
- NCT07635368
- Where
- 2 sites in Denmark
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Cmv Congenital, CMV Viremia
Cytomegalovirus (CMV) Vaccines: Reinfection and Antigenic Variation
The objectives of the protocol are to determine if a structured cognitive-behavioral interventional counseling of pregnant women can limit acquisition of human cytomegalovirus (HCMV) during pregnancy that we believe, will in turn…
- Trial name
- CMV (NCT03443791)
- Testing
- Women Enrolled, Newborns of Female Study Participants
- Where
- Brazil
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Infections, Cytomegalovirus
A Study in Adolescent Females to Explore Cytomegalovirus Infection
The purpose of this study is to estimate the incidence of Cytomegalovirus (CMV) secondary infections (re-infections/re-activations) and the incidence of CMV primary infections in adolescent females.
- Trial name
- NCT01691820
- Testing
- Blood collection, Urine collection, Saliva collection
- Where
- 5 sites in United States, Finland and 1 more
- Volunteers
- 369 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation (HSCT)
Clinical Performance of SE-SPTM-PCR in Detecting Hcmv-miR-UL22A-5p After Hematopoietic Stem Cell Transplantation
This study aims to evaluate the clinical performance of a novel microRNA-based detection platform, SE-SPTM-PCR, for identifying cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (HSCT).
- Conditions
- Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation (HSCT), CMV Reactivation, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
- Trial name
- SESPTM-CMV (NCT07181330)
- Testing
- SE-SPTM-PCR microRNA assay
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ting YANG
HCMV Infection, Hypertension
The Link Between Human Cytomegalovirus (HCMV) and Hypertension
It has been reported that mouse cytomegalovirus infection alone can elevate the blood pressure in mice. Since HCMV has uniquely evolved with its human host, with little genetic similarity to the animal CMV counterparts, and it…
- Trial name
- NCT01113359
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Beijing Chao Yang Hospital
CMV Infection, EBV
Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation
To assess the safety and biological efficacy of therapeutically administered most closely HLA-matched third party donor-derived specific cytotoxic T lymphocytes (CTLs) targeting cytomegalovirus (CMV) or Adenovirus (Adv) or…
- Conditions
- CMV Infection, EBV, Adenovirus
- Trial name
- R3ACT (NCT02779439)
- Testing
- Virus specific CTLs
- Where
- Australia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Sydney
Influenza
Response of Older Adults to Influenza Vaccination With Regard to Cytomegalovirus (CMV) Status
The study is being undertaken to evaluate responses to seasonal influenza vaccine in older adults with respect to their CMV status.
- Trial name
- CMVflu (NCT00442975)
- Testing
- Fluarix
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Public Health England
Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing…
- Conditions
- Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT07020533
- Testing
- Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation
- Where
- 3 sites in United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Cytomegalovirus Infections
Recombinant CMV gB Vaccine in Postpartum Women
The purpose of this study is to determine if a new cytomegalovirus (CMV) vaccine (CMV gB/MF59) can safely prevent mothers from catching CMV infection between pregnancies.
- Trial name
- NCT00125502
- Testing
- CMV gB vaccine, MF59 adjuvant
- Where
- 2 sites in United States
- Volunteers
- 464 people, healthy volunteers welcome
- Sponsor
- Robert Pass, MD
Infections, Cytomegalovirus
Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult Subjects
This will be the first time in humans (FTIH) study with the GSK Bio recombinant gB antigen to evaluate safety and immunogenicity of this CMV candidate vaccine with a proprietary GSK adjuvant system.
- Trial name
- NCT00435396
- Testing
- GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A
- Where
- 2 sites in Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV I Infection
To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV
The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity of VIR 1388 in adults in good health without HIV.
- Trial name
- NCT05854381
- Testing
- VIR-1388
- Where
- 10 sites in United States, South Africa
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)